Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA
extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial
with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS
methylphenidate and placebo. Each week, parent report measures, clinical interviews, and
safety assessments are conducted.
Hypothesis: Efficacy and adverse events will be dose dependent. Dopamine Transporter Genotype
will predict response